Gross Profit Trends Compared: Corcept Therapeutics Incorporated vs MorphoSys AG

Biotech Giants' Profit Trends: Corcept vs MorphoSys

__timestampCorcept Therapeutics IncorporatedMorphoSys AG
Wednesday, January 1, 20142566900063900978
Thursday, January 1, 201548925000106145897
Friday, January 1, 20167926300049646515
Sunday, January 1, 201715564700066757840
Monday, January 1, 201824603200074645876
Tuesday, January 1, 201930098200059670105
Wednesday, January 1, 2020348292000318524319
Friday, January 1, 2021360697000147400000
Saturday, January 1, 2022396473000229647003
Sunday, January 1, 2023475894000179923313
Loading chart...

Unleashing the power of data

Gross Profit Trends: Corcept Therapeutics vs MorphoSys AG

In the ever-evolving landscape of biotechnology, understanding financial trends is crucial. This analysis compares the gross profit trajectories of Corcept Therapeutics Incorporated and MorphoSys AG from 2014 to 2023. Corcept Therapeutics has shown a remarkable growth, with its gross profit increasing by over 1,750% during this period. Starting at just 26 million in 2014, it soared to nearly 476 million by 2023. In contrast, MorphoSys AG experienced a more volatile journey, peaking in 2020 with a gross profit of approximately 319 million, before settling at around 180 million in 2023. This comparison highlights Corcept's consistent upward trend, while MorphoSys faced fluctuations. Such insights are invaluable for investors and stakeholders aiming to navigate the biotech sector's financial dynamics.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025